News

Bayer has announced successful results from a Phase III clinical trial evaluating its investigational PET tracer, iodine 124 evuzamitide, designed for diagnosing…

This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…

People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the…

The American Heart Association launches cluster randomized trial to improve detection of ATTR cardiomyopathy within hospitals participating in Get With The…

TOPLINE:Most older adults with transthyretin cardiac amyloidosis (ATTR-CM) experienced at least 6 months of delay in diagnosis after a first heart failure (HF)…

AbstractBackgroundCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy associated with conduction disease and arrhythmias, although their true…

AbstractBackgroundCardiac amyloidosis is frequently underdiagnosed and rarer forms (e.g., non-transthyretin or light chain amyloidosis) can be challenging to…

AbstractBACKGROUND:Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded…

Recent research shows that Bayer's investigational PET radiotracer Iodine 124 Evuzamitide meets primary endpoints in Phase III study in patients suspected to…

AbstractObjectivesThe aim of this study was to compare the sensitivity of nerve biopsy, fat aspirate, and skin biopsy in detecting amyloid in symptomatic hereditary…